| 前收市價 | 53.55 |
| 開市 | 54.09 |
| 買盤 | 51.08 x 300 |
| 賣出價 | 51.19 x 300 |
| 今日波幅 | 51.02 - 54.89 |
| 52 週波幅 | 37.55 - 91.10 |
| 成交量 | |
| 平均成交量 | 1,695,433 |
| 市值 | 4.552B |
| Beta 值 (5 年，每月) | 無 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -1.94 |
| 業績公佈日 | 2024年5月08日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 84.42 |
ZacksCRISPR's (CRSP) Q1 Loss Narrower-Than-Expected, Sales Miss
CRISPR Therapeutics (CRSP) reports mixed earnings results for first-quarter 2024. Management claims that the commercial launch for the first ever CRISPR-based gene therapy is progressing well.
ZacksCRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Misses Revenue Estimates
CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of 12.27% and 93.94%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
ZacksCRISPR (CRSP) to Report Q1 Earnings: What's in the Cards?
On CRISPR Therapeutics' (CRSP) first-quarter 2024 earnings call, investors' focus is likely to be on the updates related to the first sales numbers of its newly approved gene therapy, Casgevy.
